Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst 2002; 94(18): 1344-5.Gruber SB, Petersen GM. Cancer risks in BRCA1 carriers: time for the next generation of studies (Editorial). J Natl Cancer Inst 2002;94:1344 - 45....
1、Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., ... & Goldgar, D. E. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Jama, 317(23), 2402-2416. 2、Ran...
[4]Hu C, Hart SN, Polley EC, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018;319(23):2401-2409. doi:10.1001/jama.2018.6228 [5]Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl C...
美国FDA批准的靶向癌症治疗也在迅速扩大,包括PARP抑制剂,用于与BRCA1/2胚系突变相关的乳腺癌、胰腺癌和前列腺癌治疗。 近日,美国华盛顿大学研究团队在JAMA Oncology上发表了题为“BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients”的综述文章,总结了BRCA1/2与癌症风险、靶向癌症治疗方案...
[3]Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. British Journal of Cancer 2007; 96(1):11–15. [4]Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. Journal of Clinical Oncology 2009; 27(...
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male PatientsA Review Heather H. Cheng, MD, PhD1,2; Jeffrey W. Shevach, MD3; Elena Castro, MD, PhD4; et al Fergus J. Couch, PhD5; Susan M. Domchek, MD6; Rosalind A. Eeles, PhD7; Veda N. Giri, MD8; Michael J...
[5]Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-1316. doi:10.1093/jnci/91.15.1310 [6]Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA...
BRCA1 and BRCA2 mutations increase breast and ovarian cancer risks substantially enough to warrant risk reduction surgery, despite variable risk estimates. Underlying this variability are methodological issues, and also complex genetic and nongenetic effects. Although many modifying factors are unidentified,...
[1] Kuchenbaecker, K. B., et al. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Jama. DOI:10.1001/jama.2017.7112 [2] Ransburgh, D. J., et al. (2010). Identification of breast tumor mutations in BRCA1 that abolish its functi...
[1]. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112 [2]. Walsh T, Gulsuner S, Lee MK, et al. Inherited predisposition to breast...